Goldman Sachs Maintains Neutral on Immunovant, Raises Price Target to $32

Benzinga Newsdesk www.benzinga.com Positive 65.8%

Neg 0% Neu 0% Pos 65.8%

Goldman Sachs analyst Corinne Johnson maintains Immunovant (NASDAQ:IMVT) with a Neutral and raises the price target from $29 to $32.